Corcept Therapeutics (CORT) news
Recent news
Corcept Therapeutics Incorporated shares rise over 19% pre-market, currently trading at $111.50.
AInvest Wire · Jul 30, 2026Corcept Therapeutics Inc.: H.C. Wainwright raises target price to $165 from $95
H.C. Wainwright has raised its price target for Corcept Therapeutics Inc. (NASDAQ:CORT) to $165 from $95, while maintaining its Buy rating. This adjustment follows Corcept’s first-quarter 2026 financial results, which showed total revenues of approximately $165 million , below the consensus…
AInvest Wire · Jul 30, 2026Corcept Therapeutics Inc: Canaccord Genuity raises target price to $161 from $150
AInvest Wire · Jul 30, 2026Corcept sees FY revenue $1.1B to $1.2B, saw $950M to $1.05B
AInvest Wire · Jul 29, 2026Corcept shares climb 15% after boost in revenue guidance
Corcept Therapeutics (Nasdaq: CORT) shares rose 15% following an upward revision of its revenue guidance, signaling improved financial performance expectations for the company. The adjustment reflects stronger-than-anticipated demand for its products and better-than-expected operational execution.…
AInvest Wire · Jul 29, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.